Over 40 years have elapsed since the large-scale introduction of the cervical-cancer smear as a cancer detection tool. The smear, which consists of a sample of cells from the epithelial surfaces of the uterine cervix, is colloquially known as the "Pap test," after its discoverer, George N. Papanicolaou. The test is performed annually on many millions of women. It has contributed in a statistically significant way to the reduction of morbidity and mortality rates from invasive carcinoma of the uterus in appropriately screened populations {1-4). However, the test is prone to disturbing failures (5).
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Theoretically, at least, the test is quite simple: the cell samples, placed on microscope slides and appropriately stained, are studied under the microscope by trained cytotechnologists. The presence of precancerous lesions is heralded by the appearance of nuclear and cytoplasmic abnormalities. Tissue biopsies, preferably obtained with the colposcope, a magnifying instrument, provide further information on the scope and size of the lesion, which is subsequently removed or destroyed to prevent its progression to invasive cancer.
In practice, there are several problems with the Pap test. They are (a) the adequacy of the samples, (b) the difficulty of microscopic screening, based on recognizing few abnormal cells among many thousands of cells in each sample, and (c) the compliance of patients with testing at appropriate intervals or with follow-up procedures. These problems have been the subject of considerable concern in the lay press and in scientific publications (5) . The failure to discover a precancerous lesion before it becomes malignant has resulted in invasive cancer and death of some young patients.
Measures to improve the quality of screening have been recently proposed (Amendment to the Clinical Laboratory Improvement Act: pending), but, without adequate funding, the implementation and results of these measures are uncertain.
One of the key issues in providing adequate care to patients at risk for cervical cancer is the manner in which the smears are reported to the primary care physicians and gynecologists. Papanicolaou, who was not a trained pathologist, recognized early in his work that he was not qualified to render diagnostic verdicts based on smears. He therefore devised a system of reporting based on five classes. Class I smears were entirely benign, hence normal. Class II smears disclosed minor cell abnormalities ("atypia"), thought to be benign. Class III smears corresponded to cell abnormalities that were "suspicious," but not definitely cancerous. Class IV smears were "most likely malignant," and Class V smears were unequivocally malignant and diagnostic of cancer.
This reporting system was widely adopted in the United States and abroad but was rarely used as originally intended. Instead, the significance of classes was often modified. In some laboratories, Class II smears were considered to be suspicious, Class III smears were considered to indicate precancerous lesions, and Class IV smears were considered to indicate invasive cancer. Other laboratories used only three classes. Still further variations in the theme existed, including subdivision of the classes by letters, such as III A and IIIB.
The issue became even more complicated once tissue pathologists entered the act. It was recognized fairly early in the mass-screening process that the rate of discovery of precancerous lesions of the cervical epithelium was much higher than the true or projected incidence of invasive cancer. Hence, there were at least some precancerous lesions that did not have the potential for progression to invasive cancer. Some observers thought that the cytologic and histologic appearance of these lesions might provide the clue to their behavior. Thus, despite some dissenting voices {6,7), the lesions were divided into two broad categories: dysplasia and carcinoma in situ. Dysplasia referred to lesions with a lower degree of abnormality that were implicitly less likely to progress to invasive cancer. Carcinoma in situ referred to lesions that were implicitly more likely to progress to invasive cancer. Dysplasia was further subdivided into three grades (mild, moderate, and severe) that were presumed to reflect the potential for "good" or "worse" behavior {8). It was also proposed that one could accurately interpret the cervical smear in terms of the underlying tissue pattern.
These additional classifications had a profound impact on the reporting system. Because of significant peer pressure, pathologists felt compel led to add a comment on the nature, and hence the probable behavior, of the underlying lesion to every abnormal smear report. This system of reporting was based on the premise that the interpretation of smears and biopsies was reproducible. Unfortunately, in spite of some efforts {8), the precancerous lesions known as dysplasias have never been objectively defined. Numerous surveys among expert pathologists clearly showed that the diagnostic system was not reproducible and that one person's dysplasia was another person's carcinoma and vice versa {9,10). Further, long-term follow-up studies documented that the behavior of precancerous lesions could not be predicted by morphology (6) .
The clinicians at the receiving end of the cytologic reports were often unaware of the substance and nature of the controversy and acted (or failed to act) according to their interpretation of the classes and verbal comments. There is evidence that women with Class III smears or "dysplasia" were not always treated and subsequently developed invasive cancer {11). Because of the diagnostic chaos, it became impossible to compare the results from laboratories and individual pathologists.
Richart's introduction of the concept of "cervical intraepithelial neoplasia" (CIN) (12) , encompassing all of the precancerous lesions of the epithelium of the uterine cervix, constituted a major breakthrough. Many gynecologists recognized that reports on cervical smears were not always accurate and that many women with "atypia" or "mild dysplasia" have precancerous lesions requiring colposcopy and treatment. This knowledge, however, did not necessarily drift down to the primary care physicians or alleviate the need for a uniform reporting system of cervical smears.
A group of experts, representing a broad spectrum of interested professional organizations, met in Bethesda, Md, under the auspices of the National Cancer Institute on December 12 and 13, 1988. They met in an attempt to redefine the reporting system of the cervical smears and to address several other pertinent issues (13) (table 1) , was adopted by consensus and, hopefully, will introduce order and uniformity into the diagnostic chaos that prevailed until now.
The key points of the Bethesda System are as follows: I. The cytology report is a medical consultation. This statement separates the cervical smear from machine-generated clinical laboratory tests and proposes a different role for the smear in the cancer prevention system. It holds clinician responsible for obtaining an adequate sample and for providing an adequate medical history. It obligates the cytopathologist to assess the adequacy of the sample, that is, whether it is representative of the status of the cervical epithelium. The statement also obligates the pathologist to provide guidance to the clinician in further evaluation of the patient, if required. II. The Papanicolaou reporting system of smear classes was not considered adequate. The lack of uniformity and uncertainty of the message conveyed by classes was judged to be ill-suited to the practice of preventive medicine.
III. A new reporting system was proposed. The proposed reporting system is the heart of the Bethesda document because it requires that each report should determine several aspects of the cervical sample. (The Bethesda System proposal does not preclude the use of other nomenclature as an addendum to the principal reporting system.) Requirements for the report are as follows:
A. Adequacy of smears. The adequacy of each sample must be assessed. If the sample is thought to be inadequate, an explanation of the reasons for this judgment must be provided. This provision has significant fiscal implications: for a smear to be judged as inadequate, it must be processed and screened. The costs of this procedure must be borne by the patients or third-party payers, and obtaining another smear clearly implies additional costs. Thus, it is in the interest of the clinicians and the patients to provide adequate smears on the first attempt. On the other hand, rejecting a smear as inadequate requires good judgment by the pathologist, and this decision must be based on solid grounds. Because the makeup of the smear may vary according to the clinical situation, sampling instruments, age, and menstrual status of the patient, these factors must be taken into account. Needless to say, reporting an inadequate smear as negative in a patient who subsequently develops invasive cervical cancer may have major legal consequences.
B. Primary assessment. The reporting of the sample falls into two categories: within normal limits and "other," which calls for descriptive diagnosis. C. Descriptive diagnosis of benign abnormalities. The descriptive diagnosis of benign abnormalities includes a broad variety of infections and infestations and reactive changes. D. Descriptive diagnosis of precancerous lesions. In reference to the precancerous intraepithelial lesions, the significant thrust of the Bethesda System is the classification of these lesions into two categories: low-grade and high-grade. The low-grade lesions include all neoplastic changes, previously classified as "mild dysplasia," CIN I, or lesions with morphologic changes suggestive of human papillomavirus infections (e.g., flat condylomas). The high-grade lesions comprise all other precancerous events or lesions previously classified as moderate or marked dysplasia and carcinoma in situ (CIN II and III). Thus, the reporting of precancerous lesions is much simplified. E. Descriptive diagnosis of cancer. Additional reporting categories have been provided to encompass other abnormalities, including various types of invasive cancer that can be recognized in the cervical samples.
The goal of the Bethesda System is to introduce a uniform reporting system for cervical smears. This is an important first step in introducing a national system of quality control. The mandatory reporting of inadequate samples may have a major impact on the quality of the smears. Patients' compliance with testing at appropriate intervals and/or with follow-up procedures, on the other hand, will not be directly affected, short of a major media campaign.
Is the Bethesda System a final document that will once and for all eliminate all problems with providing, screening, and reporting cervical smears? Will it introduce uniform clinical handling of these lesions? And finally, will the system eliminate invasive cervical cancer, which is a preventable disease? This writer has some doubts about it. The reporting system as such is only one part of a complex cancer detection process (5) . The reproducibility of the diagnostic system, even with the simplified classification of low-grade and high-grade precancerous lesions must still be tested. While this subdivision is possible in the morphologic sense, it still does not imply that the handling of the patients should be different.
Although there is fairly good evidence that many of the low-grade lesions will disappear spontaneously, many exceptions to this rule exist. Further, no statistical analysis performed to date indicates how many high-grade lesions are represented in the smears classified as low-grade lesions. Anecdotal experience suggests that this occurrence is not uncommon. Thus, colposcopy of all the lesions, whether low-or high-grade, is still the prudent way to proceed.
Undoubtedly, with the passage of time, perhaps in the next century, molecular biologic probes will become available. These probes will allow an accurate prediction of the behavior of precancerous lesions, a task that unfortunately is not possible today by morphologic examination of the cytologic samples or tissue samples or by typing of human papillomaviruses (14) .
However, the Bethesda System is a good beginning. As the writers of the document stated, like any other human endeavor, this document can be amended in the future. At this time, it is worthy of a major trial on a national scale, provided that the results are collated and evaluated. To my knowledge, no effort has been made so far to create an agency that would assess the results.
